Compare Sun Pharma with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs WYETH LTD - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA WYETH LTD SUN PHARMA/
WYETH LTD
 
P/E (TTM) x 509.5 27.7 1,837.8% View Chart
P/BV x 3.1 5.3 58.8% View Chart
Dividend Yield % 0.5 1.3 39.9%  

Financials

 SUN PHARMA   WYETH LTD
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
WYETH LTD
Mar-13
SUN PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs6791,044 65.0%   
Low Rs375818 45.9%   
Sales per share (Unadj.) Rs121.1298.6 40.6%  
Earnings per share (Unadj.) Rs13.457.2 23.4%  
Cash flow per share (Unadj.) Rs20.758.4 35.4%  
Dividends per share (Unadj.) Rs2.7517.00 16.2%  
Dividend yield (eoy) %0.51.8 28.6%  
Book value per share (Unadj.) Rs172.6249.5 69.2%  
Shares outstanding (eoy) m2,399.2622.72 10,560.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.43.1 139.5%   
Avg P/E ratio x39.416.3 242.2%  
P/CF ratio (eoy) x25.515.9 159.9%  
Price / Book Value ratio x3.13.7 81.8%  
Dividend payout %20.629.7 69.2%   
Avg Mkt Cap Rs m1,264,65021,157 5,977.5%   
No. of employees `00017.50.5 3,557.1%   
Total wages/salary Rs m59,671400 14,917.7%   
Avg. sales/employee Rs Th16,608.113,787.4 120.5%   
Avg. wages/employee Rs Th3,409.6813.0 419.4%   
Avg. net profit/employee Rs Th1,833.82,643.3 69.4%   
INCOME DATA
Net Sales Rs m290,6596,783 4,284.9%  
Other income Rs m10,255353 2,908.4%   
Total revenues Rs m300,9147,136 4,216.8%   
Gross profit Rs m63,0761,617 3,900.1%  
Depreciation Rs m17,53327 65,911.7%   
Interest Rs m5,5536 100,954.5%   
Profit before tax Rs m50,2461,938 2,592.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,144-5 238,113.7%   
Tax Rs m6,009632 950.5%   
Profit after tax Rs m32,0931,301 2,467.8%  
Gross profit margin %21.723.8 91.0%  
Effective tax rate %12.032.6 36.7%   
Net profit margin %11.019.2 57.6%  
BALANCE SHEET DATA
Current assets Rs m310,6926,984 4,448.7%   
Current liabilities Rs m173,3962,056 8,434.1%   
Net working cap to sales %47.272.6 65.0%  
Current ratio x1.83.4 52.7%  
Inventory Days Days9999 99.8%  
Debtors Days Days11224 466.0%  
Net fixed assets Rs m232,477244 95,160.4%   
Share capital Rs m2,399227 1,056.0%   
"Free" reserves Rs m411,6915,441 7,566.7%   
Net worth Rs m414,0915,668 7,305.8%   
Long term debt Rs m15,22625 60,904.4%   
Total assets Rs m646,9387,901 8,188.1%  
Interest coverage x10.0353.3 2.8%   
Debt to equity ratio x00 833.6%  
Sales to assets ratio x0.40.9 52.3%   
Return on assets %5.816.5 35.2%  
Return on equity %7.822.9 33.8%  
Return on capital %10.234.0 29.9%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m66,02515 434,377.6%   
Fx outflow Rs m38,6102,677 1,442.2%   
Net fx Rs m27,415-2,662 -1,029.9%   
CASH FLOW
From Operations Rs m21,965923 2,379.2%  
From Investments Rs m-6,813317 -2,149.7%  
From Financial Activity Rs m-27,305-481 5,676.8%  
Net Cashflow Rs m-8,442759 -1,112.0%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 5.1 11.3 45.4%  
FIIs % 23.0 7.2 319.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 30.4 27.3%  
Shareholders   133,026 21,978 605.3%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  PANACEA BIOTECH  WOCKHARDT  

Compare SUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 225 Points Higher; Metal and Banking Stocks Witness Buying(Closing)

Extending gains to the fourth consecutive session, Indian share markets witnessed buying interest throughout the day today and ended higher.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 11, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS